uniQure N.V. (QURE)
uniQure N.V. is a biotechnology company focused on developing gene therapy treatments for genetic and other life-threatening diseases. Founded in the Netherlands, it specializes in delivering gene therapies using adeno-associated virus (AAV) vectors to address rare, serious conditions such as hemophilia and neurological disorders.
Company News
uniQure, a gene therapy company, has appointed Kylie O'Keefe as Chief Customer and Strategy Officer to lead the commercialization of its investigational gene therapy AMT-130 for the treatment of Huntington's disease.
CSL Behring's gene therapy HEMGENIX has shown sustained efficacy and safety in treating adults with hemophilia B, with 94% of patients remaining free of continuous prophylaxis treatment four years after a single infusion.
uniQure (QURE) delivered earnings and revenue surprises of 0.65% and 109.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The company announced a reorganization that included layoffs.
uniQure's share price took a 30% dip following the release of its Phase-1/2 clinical trial data on AMT-131. QURE represents a good entry point for investors.